Bayer HealthCare licenses Isis' antisense thrombosis candidate
Bayer HealthCare Pharmaceuticals AG licensed exclusive development and commercialization rights to Isis Pharmaceuticals Inc.'s ISIS-FXIRx (formerly ISIS416858), a Factor XI inhibitor in Phase II for thrombosis prevention.
- Antisense, Oligonucleotides
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com